51 articles for thisTarget

---

The following articles (labelled with PubMed ID or TBD) are for your review

PMID	Data	Article Title	Organization
28280261	84	Non-kinase targets of protein kinase inhibitors.	The University of Sydney
27474927	76	Synthesis, biological evaluation and molecular modeling studies of imidazo[1,2-a]pyridines derivatives as protein kinase inhibitors.	Paris-Sud University
26771245	7	Recent developments of 2-aminothiazoles in medicinal chemistry.	Sree Chaitanya College
26762835	342	Discovery of 2-(1H-indol-5-ylamino)-6-(2,4-difluorophenylsulfonyl)-8-methylpyrido[2,3-d]pyrimidin-7(8H)-one (7ao) as a potent selective inhibitor of Polo like kinase 2 (PLK2).	Icahn School of Medicine At Mount Sinai
25899335	1	Synthesis and identification of unprecedented selective inhibitors of CK1e.	Instituto Universitario De Bio-Org£Nica Antonio Gonz£Lez (Iubo-Ag)
25191940	48	Difluoro-dioxolo-benzoimidazol-benzamides as potent inhibitors of CK1d ande with nanomolar inhibitory activity on cancer cell proliferation.	Ulm University Hospital
23919824	18	Ligand-protein interactions of selective casein kinase 1d inhibitors.	Pfizer
22749643	69	Structure-based optimization of oxadiazole-based GSK-3 inhibitors.	Technische Universit£T Darmstadt
22944772	15	Discovery of N6-phenyl-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamine derivatives as novel CK1 inhibitors using common-feature pharmacophore model based virtual screening and hit-to-lead optimization.	TBA
22726925	216	Discovery of 5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-N-(tert-butyl)pyridine-3-sulfonamide (CZC24758), as a potent, orally bioavailable and selective inhibitor of PI3K for the treatment of inflammatory disease.	Cellzome
23106386	4	Structural basis for the potent and selective inhibition of casein kinase 1 epsilon.	Amgen
22533818	84	Identification of glycogen synthase kinase-3 inhibitors with a selective sting for glycogen synthase kinase-3a.	Technische Universit£T Darmstadt
18183025	12060	A quantitative analysis of kinase inhibitor selectivity.	Ambit Biosciences
18077363	314	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.	University of Oxford
22168824	4	Structural basis for the interaction between casein kinase 1 delta and a potent and selective inhibitor.	Amgen
22037378	31824	Comprehensive analysis of kinase inhibitor selectivity.	Ambit Biosciences
21807510	31	Synthesis and biological evaluation of glycogen synthase kinase 3 (GSK-3) inhibitors: an fast and atom efficient access to 1-aryl-3-benzylureas.	Technische Universit£T Darmstadt
21375264	77	Discovery of 6-(2,4-difluorophenoxy)-2-[3-hydroxy-1-(2-hydroxyethyl)propylamino]-8-methyl-8H-pyrido[2,3-d]pyrimidin-7-one (pamapimod) and 6-(2,4-difluorophenoxy)-8-methyl-2-(tetrahydro-2H-pyran-4-ylamino)pyrido[2,3-d]pyrimidin-7(8H)-one (R1487) as orally bioavailable and highly selective inhibitors	Roche Palo Alto
19654408	2521	AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML).	Ambit Biosciences
19950901	23	Selective p38alpha inhibitors clinically evaluated for the treatment of chronic inflammatory disorders.	Roche Palo Alto
19837585	46	Evaluation of substituted 6-arylquinazolin-4-amines as potent and selective inhibitors of cdc2-like kinases (Clk).	National Human Genome Research Institute
19591487	38	3,4-Diaryl-isoxazoles and -imidazoles as potent dual inhibitors of p38alpha mitogen activated protein kinase and casein kinase 1delta.	Eberhard-Karls University
	4	Benzo[c]quinoliziniums: A new family of inhibitors for protein kinase CK II	TBA
16366598	51	(6,7-Dimethoxy-2,4-dihydroindeno[1,2-c]pyrazol-3-yl)phenylamines: platelet-derived growth factor receptor tyrosine kinase inhibitors with broad antiproliferative activity against tumor cells.	Johnson & Johnson Pharmaceutical Research and Development
15999992	25	Synthesis and identification of [1,3,5]triazine-pyridine biheteroaryl as a novel series of potent cyclin-dependent kinase inhibitors.	Johnson & Johnson Pharmaceutical Research and Development
15711537	653	A small molecule-kinase interaction map for clinical kinase inhibitors.	Ambit Biosciences
12941331	96	Macrocyclic bisindolylmaleimides as inhibitors of protein kinase C and glycogen synthase kinase-3.	Johnson & Johnson Pharmaceutical Research & Development
31757666	314	Discovery and optimization of heteroaryl piperazines as potent and selective PI3K? inhibitors.	Merck
31647655	114	Kinase Chemodiversity from the Arctic: The Breitfussins.	Uit - The Arctic University of Norway
31400711	29	Small molecule modulators targeting protein kinase CK1 and CK2.	China Pharmaceutical University
30385160	10	Decreasing the CYP2D6 contribution to metabolism of a CK1? inhibitor.	Sanofi Us
30384048	365	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.	University of Florida
30978288	113	A Selective and Brain Penetrant p38?MAPK Inhibitor Candidate for Neurologic and Neuropsychiatric Disorders That Attenuates Neuroinflammation and Cognitive Dysfunction.	Northwestern University
29630366	42	Discovery of Inhibitor of Wnt Production 2 (IWP-2) and Related Compounds As Selective ATP-Competitive Inhibitors of Casein Kinase 1 (CK1) ?/?.	Ulm University Hospital
29289448	127	Development of dual casein kinase 1?/1? (CK1?/?) inhibitors for treatment of breast cancer.	Scripps Florida
29016121	44	Synthesis, Binding Mode, and Antihyperglycemic Activity of Potent and Selective (5-Imidazol-2-yl-4-phenylpyrimidin-2-yl)[2-(2-pyridylamino)ethyl]amine Inhibitors of Glycogen Synthase Kinase 3.	Novartis Institutes For Biomedical Research
18251489	9	Synthesis and dopamine receptor affinities of N-alkyl-11-hydroxy-2-methoxynoraporphines: N-alkyl substituents determine D1 versus D2 receptor selectivity.	Mclean Hospital
17583335	49	In vitro structure-activity relationship and in vivo characterization of 1-(aryl)-3-(4-(amino)benzyl)urea transient receptor potential vanilloid 1 antagonists.	Abbott Laboratories
9767635	42	Acetylcholinesterase inhibitors: synthesis and structure-activity relationships of omega-[N-methyl-N-(3-alkylcarbamoyloxyphenyl)- methyl]aminoalkoxyheteroaryl derivatives.	University of Bologna